Heck Johannes, Dubaschewski Melanie, Krause Olaf, Bleich Stefan, Schulze Westhoff Martin, Krichevsky Benjamin, Glahn Alexander, Schröder Sebastian
Institute for Clinical Pharmacology, Hannover Medical School, Hannover, Germany.
Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany.
Front Psychiatry. 2025 Apr 10;16:1556920. doi: 10.3389/fpsyt.2025.1556920. eCollection 2025.
This study investigates the medication knowledge of patients with substance use disorders (SUDs) treated at a psychiatric clinic in northern Germany, aiming to identify gaps in understanding and to enhance patient safety, particularly concerning ATC group A drugs.
The study was conducted in the Department of Psychiatry, Social Psychiatry, and Psychotherapy at Hannover Medical School, Germany.
A cross-sectional, interview-based study using a convenience sample of 100 patients was conducted between March 2023 and April 2024.
The cohort included patients with SUDs who had been hospitalized for at least 72 hours, regularly took at least one medication in addition to withdrawal drugs, and who displayed no cognitive impairments. Participants had a median age of 46.5 years; 62% were male.
Patients were interviewed using a customized questionnaire addressing knowledge of drug name, indication, dosage, and frequency of application. The questionnaire also assessed the sources of medication knowledge and patient opinions on their medication regimen.
The primary outcome was the average medication knowledge score (range 0-6). Secondary measures included differences in knowledge across drug groups, sources of information, and demographic influences.
The median medication knowledge score was 3.8 out of 6. Knowledge was significantly lower for ATC group A drugs compared to groups B, C, and N (p < 0.001). No significant differences were observed between men and women nor between age groups. Hospital physicians were the primary information source for 40% of patients. Most participants (84%) considered their medication regimen adequate.
Patients with SUDs demonstrated suboptimal medication knowledge, particularly regarding ATC group A drugs. Future strategies should prioritize patient education and enhanced physician engagement to improve understanding and adherence, ultimately fostering better therapeutic outcomes.
本研究调查了在德国北部一家精神病诊所接受治疗的物质使用障碍（SUDs）患者的用药知识，旨在找出理解上的差距并提高患者安全性，特别是关于解剖学治疗学及化学分类系统（ATC）A组药物。
该研究在德国汉诺威医学院精神病学、社会精神病学和心理治疗系进行。
2023年3月至2024年4月间，采用便利抽样法对100名患者进行了一项基于访谈的横断面研究。
该队列包括已住院至少72小时、除脱毒药物外定期服用至少一种药物且无认知障碍的SUDs患者。参与者的年龄中位数为46.5岁；62%为男性。
使用定制问卷对患者进行访谈，问卷涉及药物名称、适应症、剂量和用药频率等知识。问卷还评估了用药知识来源以及患者对其用药方案的看法。
主要结局是平均用药知识得分（范围0 - 6）。次要指标包括不同药物组之间的知识差异、信息来源以及人口统计学影响。
用药知识得分中位数为6分中的3.8分。与B、C和N组相比，ATC A组药物的知识得分显著更低（p < 0.001）。男性和女性之间以及不同年龄组之间未观察到显著差异。40%的患者将医院医生作为主要信息来源。大多数参与者（84%）认为他们的用药方案是合适的。
SUDs患者的用药知识欠佳，尤其是关于ATC A组药物。未来策略应优先考虑患者教育并加强医生参与，以提高理解和依从性，最终促进更好的治疗效果。
